Frailty Status and Mortality Risk in PCI; Delays in Treatment in STEMI; Arterial Events with Genetic-based Vascular Disease
In this week’s View, Dr. Eagle looks at frailty status and increased risk of mortality in patients who undergo percutaneous coronary intervention (PCI). He then discusses the timely treatment and delays in treatment of ST-segment elevation myocardial infarction (STEMI) that are associated with worse outcomes. Finally, Dr. Eagle explores new insights on arterial events associated with heritable thoracic aortic disease and the relative risk in patients with pathogenic variants, as well as the prevalence, characteristics, and clinical outcomes of arterial aneurysms in Loeys-Dietz Syndrome. Subscribe to Eagle’s Eye View
--------
7:28
--------
7:28
LAAO and the Watchman FLX; HF Care in Private Equity Hospitals; Long-term Outcomes in TR and Mitral Valve-in-Valve Replacement
In this week’s View, Dr. Eagle looks at the lower risk of major adverse events in patients with left atrial appendage occlusion (LAAO) using the Watchman 2.4 device. He then discusses the impact of heart failure (HF) care in private equity hospitals in the United States. Finally, Dr. Eagle explores the long-term outcomes of patients with tricuspid regurgitation (TR) undergoing mitral valve-in-valve (MViV) replacement. Subscribe to Eagle’s Eye View
--------
6:41
--------
6:41
Marijuana Use & Endothelial Function; CV & Bleeding With Aspirin v. Clopidogrel; Mental Health for Survivors of SCA and ICD Shock
In this week’s View, Dr. Eagle looks at chronic marijuana smoking and THC-edible use and its impairment of endothelial function. He then discusses the cardiovascular (CV) and bleeding effects of aspirin versus clopidogrel in patients with acute coronary syndromes. Finally, Dr. Eagle explores the importance of addressing mental health symptoms in survivors of sudden cardiac arrest (SCA) who experience shocks from an implantable cardioverter-defibrillator (ICD). Subscribe to Eagle’s Eye View
--------
6:47
--------
6:47
Carvedilol To Treat HFimpEF; Modifiable Lifestyle Factors & Cardiac Conduction Disease; Amiloride vs. Spironolactone for Resistant Hypertension
In this week’s View, Dr. Eagle looks at the CATHEDRAL-HF Trial and its study of carvedilol’s effectiveness as a monotherapy in heart failure with improved ejection fraction (HFimpEF). He then discusses the use of modifiable lifestyle factors to lower the risk of cardiac conduction disease. Finally, Dr. Eagle explores the use of amiloride versus spironolactone for the treatment of resistant hypertension. Subscribe to Eagle’s Eye View
--------
7:27
--------
7:27
Colchicine vs. Placebo in Reducing CV Events; DOACs vs. Warfarin After TAVR; CSP vs. BiVP and Echo Response
In this week’s View, Dr. Eagle looks colchicine versus placebo in reducing major adverse cardiovascular (CV) events including CV death or myocardial infarction in patients with vascular disease. He then discusses insights from the Society of Thoracic Surgeons (STS)/American College of Cardiology (ACC) Transcatheter Valve Therapy (TVT) Registry in terms of direct oral anticoagulants (DOACs) versus warfarin after transcatheter aortic valve replacement (TAVR). Finally, Dr. Eagle explores the use of conduction system pacing (CSP) rather than biventricular pacing (BiVP) in achieving clinical and echocardiographic response. Subscribe to Eagle’s Eye View
Sobre Eagle's Eye View: Your Weekly CV Update From ACC.org
The weekly cardiovascular update from Kim Eagle, MD, MACC for ACC.org covering the hottest cardiovascular topics, from new clinical guidelines to practice-changing research and innovative quality initiatives and tools.
Brasil